This study aimed to characterize the association of diabetes with pregnancy in the Souss Massa Agadir population, focusing on epidemiological and clinical profiles, therapeutic aspects, and prognosis, while also identifying factors linked to glycemic control and maternal-fetal complications. We conducted a descriptive and analytical single-center cross-sectional study on 67 diabetic parturients at Hassan II University Hospital. Our findings reveal that half of the patients were aged 30-39, with 90% having low socioeconomic status, 55% from rural areas, and 34% illiterate. Common antecedents included family history of Type 2 diabetes (68.7%), spontaneous miscarriages (31.3%), and macrosomia (23.9%). Gestational diabetes was prevalent (60%), often incidentally diagnosed by fasting blood glucose (87.5%). While 52% of gestational diabetes cases managed with diet and lifestyle modifications alone, only 63% achieved balanced FBG and 49% balanced PPG. PPG (P=0.018) and BMI (P=0.020) were associated with FBG balance, while FBG (P=0.036), pre-gestational diabetes (P=0.029), and adherence to DLM (P=0.040) influenced PPG balance. Maternal-fetal complications occurred in 60% of cases, primarily urogenital infections, hydramnios, anemia, and macrosomia, with rural origin being a significant risk factor (OR: 3.56, P=0.01). These results underscore the critical need for multidisciplinary preconception care, early gestational diabetes diagnosis, and long-term metabolic follow-up to ensure better pregnancy outcomes and reduce future diabetes risk.

Background: Pediatric focal epilepsy is a common neurological disorder that requires early and effective treatment to prevent long-term cognitive and psychosocial consequences. Levetiracetam (LEV) is widely used as a first-line antiseizure medication, while brivaracetam (BRV), a newer SV2A ligand with higher binding affinity, has limited comparative data in children. Aim: Our aim is to compare the effectiveness and tolerability of BRV and LEV in children with newly diagnosed focal epilepsy. Materials and Methods: This retrospective comparative study was conducted at Mount Adora Hospital, Sylhet, Bangladesh, between July 2024 and June 2025. A total of 62 children aged 1–18 years with new-onset focal epilepsy were included, with 31 receiving LEV and 31 receiving BRV. Seizure frequency and treatment response were assessed at 2 weeks, 1 month, and 3 months. Common adverse effects of both drugs were also documented. Results: After 3 months, the mean seizure frequency was significantly lower in the BRV group (0.42) compared to the LEV group (1.58; p<0.001). Complete response was achieved in 87% of BRV patients versus 61% of LEV patients (p=0.042). Both drugs were generally well tolerated. Somnolence was reported in 12.9% of LEV and 9.7% of BRV patients. Behavioral adverse effects were more frequent with BRV (hyperactivity 19.4%, irritability 12.9%) compared to LEV (hyperactivity 3.2%, no irritability). Conclusion: Brivaracetam demonstrated superior seizure control efficacy as compared to levetiracetam in children with new-onset focal epilepsy, although behavioral adverse effects were more common.